• Gerasimos Siasos, George Lazaros, Evangelos Oikonomou, Theodoros Zografos, Dimitris Athanasiou, Manolis Vavuranakis, Alexis Antonopoulos, Vasiliki Tsigkou, Christodoulos Stefanadis, Athanasios G Papavassiliou, and Dimitris Tousoulis.
• 1st Department of Cardiology, x2018;Hippokration' Hospital, Athens, Greece.
• Cardiology. 2016 Jan 1; 134 (4): 384-8.

ObjectivesNon-ST elevation myocardial infarction (NSTEMI) is one of the most common manifestations of acute coronary syndromes (ACS). We evaluated the prognostic role of cardiac troponin I (cTnI) at presentation and peak cardiac troponin I in patients with NSTEMI.MethodsWe consecutively enrolled 215 subjects presenting with NSTEMI. Subjects were followed up for 1 year. cTnI at presentation and the peak value of cTnI were measured. The primary end point was defined as cardiovascular death, readmission to hospital with heart failure and new ACS.ResultsThe subjects who presented the primary end point (49 subjects) had significantly increased values of peak cTnI compared to subjects free of cardiovascular events [7.19 (2.97-21.32) vs. 4.09 (1.18-11.85) ng/l; p = 0.002]. Nevertheless, cTnI at presentation did not differ between subjects who presented the primary end point and those free of events (p = 0.39). Multivariate Cox regression analysis after adjustment for confounders revealed by the univariate analysis showed that for an increase in peak cTnI from 1 to 10 ng/l, there is a 60% anticipated increase in the relative risk to present the primary end point (p = 0.04).ConclusionThese findings documented the different prognostic significance of cTnI at presentation and peak cTnI in patients presenting with NSTEMI, and highlighted the importance of monitoring the levels of cTnI in this high-risk population.© 2016 S. Karger AG, Basel.

37 keywords...

hide…